Clinical Trial Update: Use of Presepsin as a Marker for Immunotherapy Administration in Pneumonia [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating presepsin as a biomarker to guide immunotherapy in pneumonia has completed, including community-acquired pneumonia and hospital-acqui…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Community-acquired Pneumonia
• Hospital-acquired Pneumonia

Snippet

Sponsor: Hellenic Institute for the Study of Sepsis | Conditions: Community-acquired Pneumonia, Hospital-acquired Pneumonia | Phase 2 | Status: COMPLETED